Xbrane To File Ranibizumab Biosimilar In Europe And US Within 12 Months
Company Confirms Trials On Track For Approval Before Lucentis EU Patent Expiry
Executive Summary
Sweden’s Xbrane is aiming to file for approval of its Xlucane (ranibizumab) biosimilar to Lucentis in Europe and the US, and license the rights for the product’s sale and marketing of in Latin America, Japan and China, in the next 12 months.